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Urokinase-type plasminogen activator (uPA) and tissue-
type plasminogen activator (tPA) are extracellular pro-
teases that play a role in synaptic plasticity and remodeling.
Psychostimulants induce both tPA and uPA in acute and
chronic drug delivery, but cocaine induces preferentially
uPA, whereas morphine and amphetamine induce pref-
erentially tPA. Specific doxycline-regulatable lentiviruses
expressing these extracellular proteases have been pre-
pared and stereotaxically injected into the nucleus ac-
cumbens. We show that tPA-overexpressing animals
show greater locomotor activity and behavioral sensiti-
zation upon morphine and amphetamine treatments.
These effects could be fully suppressed by doxycycline
or when tPA had been silenced using small interfering
RNAs (siRNAs)-expressing lentiviruses. Furthermore,
animals infected with lentiviruses expressing uPA show
enhanced conditional place preference for cocaine
compared with tPA-overexpressing animals. In contrast,
tPA-overexpressing animals when administered amphet-
amine or morphine showed greater place preference
compared with uPA-overexpressing animals. The effects
are suppressed when tPA has been silenced using spe-
cific siRNAs-expressing vectors. Tissue-type plasmino-
gen activator and uPA possibly induce distinct behaviors,
which may be interpreted according to their differential
pattern of activation and downstream targets. Taken
together, these data add further evidence for a significant
function of extracellular proteases tPA and uPA in addic-
tion and suggest a differential role of plasminogen
activators in this context.
Keywords: Activator, addiction, cocaine, drugs of abuse,
in vivo gene transfer, lentivirus, plasminogen, plasticity,
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Activity-dependent synaptic plasticity and remodeling of the
mesolimbic dopaminergic system play a crucial role in the
development of drug dependence (Nestler 2001). Changes in
the synaptic morphology may be due, at least in part, to local
extracellular proteolysis of cell adhesion and extracellular
matrix molecules. Some extracellular serine proteases of
the plasminogen activator family may modulate synaptic
adhesion and associate with long-term potentiation and
learning behavior. Tissue-type plasminogen activator (tPA)
and urokinase-type (uPA) plasminogen activator are serine
proteases, which both activate plasminogen into plasmin.
Tissue-type plasminogen activator is abundantly expressed in
the central nervous system (Bu et al. 1994; Davies et al. 1998;
Hayden & Seeds 1996; Qian et al. 1993; Seeds et al. 1995)
and participates in neurite outgrowth and neuronal develop-
ment by cleaving proteins of the extracellular matrix and
potentially forming a path for extending process (Jacovina
et al. 2001;Wu et al. 2000). Tissue-type plasminogen activator
contributes to the regulation of numerous aspects of synaptic
plasticity and remodeling. It is synthesized by neurons of
most brain regions and contributes also to adult central
nervous system physiology, inducing neuronal plasticity and
synaptic reorganization (Nakagami et al. 2000; Sappino et al.
1993). Tissue-type plasminogen activator is also induced in
the brain by electrical activity leading to synaptic remodeling
(Ripley et al. 1999). The role of uPA in the brain has also been
described, but its function still remains poorly characterized.
Its involvement in learning-related plasticity has been estab-
lished in knockout mice, but these mice were impaired in
tasks of spatial, olfactory and taste-aversion learning while
showing normal sensory and motor capabilities (Meiri et al.
1994).
A single morphine treatment induced tPA mRNA and
protein expression in neuronal cells of the nucleus accum-
bens (NAc) (Nagai et al. 2004). Morphine-induced conditioned
place preference and hyperlocomotion were significantly re-
duced in tPA-deficient (tPA knockout mice) and plasminogen-
deficient (plg knockout mice) mice, being accompanied by
a loss of morphine-induced dopamine release in the NAc. The
defect of both morphine-induced dopamine release and
hyperlocomotion in tPA knockout mice was reversed by
microinjections of either exogenous tPA or plasmin into the
NAc. These findings suggest that the tPA–plasmin system is
involved in the rewarding effects of morphine, by acutely
regulating morphine-induced dopamine release in the NAc
(Nagai et al. 2004). Furthermore, tPA is also induced in the
prefrontal cortex by acute cocaine and appears to play a
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specific role either in retention of information between ses-
sions or in behavioral inhibition in cocaine self-administration.
In addition, amphetamine also induces expression of tPA in pre-
frontal cortex and has been implicated in both behavioral sen-
sitization to psychostimulants, and in drug self-administration
(Schenk & Snow 1994). Chronic but not acute methamphet-
amine treatment dose dependently induced tPA mRNA
expression in the frontal cortex, NAc, striatum and hippocam-
pus. In the NAc, this effect could be blocked by pretreatment
with dopamine D1 and D2 receptor antagonists, indicating
that tPA is involved in rewarding effects as well as sensitiza-
tion of the locomotor-stimulating effect of metamphetamine
(Nagai et al. 2005a, 2005b).
In previous studies, we showed that uPA is strongly
induced upon cocaine delivery (Bahi et al. 2004a, 2006).
Cocaine induced two- to sixfold increase of uPA mRNA in
the mesolimbic dopaminergic pathway, including the ventral
tegmental area (VTA), the NAc and the hippocampus (Bahi et al.
2004a). Also local overexpression of uPA in these brain area,
by stereotaxic injection of a doxycycline-regulated uPA-
expressing lentivirus (LV-uPA), showed almost a 6- to 10-fold
increase in locomotor activity after cocaine treatment com-
pared with saline injection, an effect completely abolished
with doxycycline or when a dominant-negative form of uPA-
expressing lentivirus had been delivered (Bahi et al. 2004a,
2006). Furthermore, using lentiviruses expressing small inter-
fering RNAs (siRNAs) targeted against uPAmRNA, we clearly
established that uPA induces strong behavioral changes
associated with cocaine delivery (Bahi et al. 2006).
In the present paper, we compare behavioral changes
induced upon uPA and tPA expression in the NAc on
cocaine-, morphine- or amphetamine-induced behaviors.
Clearly, uPA and tPA induce distinct behaviors, which may
be interpreted according to their differential pattern of acti-
vation and downstream targets. Our data add further evi-
dence for a significant function of extracellular proteases tPA
and uPA in addiction and drug-related synaptic plasticity and
suggest a differential role of plasminogen activators in this
context.
Materials and methods
Animal work
Animals used in this experiment were maleWistar rats weighing 200–
250 g. All animal experiments were carried out in accordance with the
guidelines and regulations for Animal Experimentation, BAG, Bern,
Switzerland. All rats were naive and were used in a single experiment
only. They were housed in threes in clear plastic cages with wire grid
lids. Access to food and water was unrestricted. The animals were
kept in the animal facility maintained on a 12-h light:12-h dark cycle
(light off at 7 a.m.).
Construction of tPA-expressing lentivirus
Using total RNA from rat brain cocaine treated, the tPA complemen-
tary (cDNA) was amplified and 6 His-tagged by reverse transcription
using M-MLV-RT (Invitrogen, Basel, Switzerland) following the manu-
facturer’s instructions. We performed polymerase chain reaction
(PCR) amplification using this set of primers specific for rat tPA
(forward primer with BamHI: CGC GGG ATC CAT GAA GGG AGA
GCT GTT GTG C; reverse primer with XhoI: GCC GCT CGA GTT AAT
GAT GAT GAT GAT GAT GTT GCT TCA TGT TGT CTT GAA T.
restriction enzyme sites are in bold). The cDNA was then digested
with BamHI and XhoI and cloned into similar sites in the lentiviral
system transfer vector pTK431. A control vector construct, in which
green fluorescent protein (GFP) expression is regulated by a tetracy-
cline-inducible promoter, was generated by cloning a BamHI/BglII
DNA fragment containing the GFP gene into a BamHI site in pTK431
(Bahi et al. 2004a, 2004b, 2005a, 2005b, 2006). Besides, LV-uPA and
LV-uPA-Mut production were performed as described previously
(Bahi et al. 2004a, 2006).
Construction of tPA-specific siRNAs-expressing
lentiviral vectors
To silence tPA expression in vitro and in vivo, three targets were
designed, according to the rat tPA mRNA sequence (GenBank
accession no. M23697). The following targets within the tPA
sequence were selected: first target, 2–25; second target, 1650–
1673; and third target, 733–756. To each oligo, an XhoI restriction site
was 30 added. Using the pSilencer 1.0-U6 (Ambion, Huntington, UK)
as a template and an U6 promoter-specific forward primer containing
BamHI (In bold) restriction site GCG GAT CCC GCT CTA GAA CTA
GTG C, each siRNA target was added to the mouse U6 promoter by
PCR (each target contains a 30-specific U6 promoter-specific primer).
The PCR conditions were highly drastic to avoid mutations within the
targets. The following PCR program was performed: 120 seconds at
948C (initial denaturation) followed by 948C for 45 seconds, 648C for
45 seconds and 728C for 45 seconds, repeated for 35 cycles. The PCR
reaction contains 4% dimethyl sulfoxide (Sigma, Buchs, Switzerland).
The PCR product was digested with BamHI and XhoI, cloned into
similar sites in pTK431 and sequenced to verify the integrity of each
construct.
After cloning and sequencing, all plasmids were CsCl2 purified.
Vesicular stomatitis virus G pseudotyped lentiviruses were produced
by the transient calcium phosphate cotransfection of HEK293T cells
with pTKs vectors together with pMDG-VSV-G and pDNRF as pre-
viously described (Bahi et al. 2004a, 2004b, 2005a, 2005b, 2006).
Lentiviral vector quantifications were performed according to the
p24 enzyme-linked immunosorbent assay (KPL, Gaithersburg, MD,
USA) in accordance with the manufacturer’s instructions. Besides,
uPA-specific siRNAs-expressing lentiviral vectors (LV-uPA-siRNAs)
(for silencing uPA) have been described previously (Bahi et al. 2006).
In vitro experiments
For doxycycline regulation, HEK293T cells were infected with 0, 3, 6
or 9 ml from viral stock of tPA-expressing lentivirus (LV-tPA) together
with 4 ml of LV-uPA (Bahi et al. 2004a, 2006). Culture medium was
supplemented with 30 ng/ml of doxycycline. After 72 h, culture
medium was removed and cells were used for total RNA extraction.
To test the knock-down effect of tPA expression with tPA-specific
siRNAs-expressing lentiviral vectors (LV-tPA-siRNAs) in vitro, cells
were infectedwith 3 ml of LV-tPA, together with 4 ml of LV-uPA; knock-
down was performed by adding either 2 ml of LV-tPA-siRNA1, 2 ml of
LV-tPA-siRNA2, 2 ml of LV-tPA-siRNA3 or 2 ml of the three targets
together. After 72 h, culture medium was removed and cells were
used for total RNA extraction.
Real-time PCR and tPA mRNA quantification
Total RNA was extracted from the HEK293T cells using Trizol reagent
(Invitrogen) according to the manufacturer’s instructions. RNA was
quantified by spectrophotometry, and its integrity was verified by
agarose gel electrophoresis and visualized with ethidium bromide
staining. First-strand cDNA was generated from 4 mg of total RNA
and oligo(dT12–18) primer with the M-MLV-RT (Invitrogen) in a total
volume of 20 ml according to the manufacturer’s protocol. To quantify
the tPA mRNA level, quantitative real-time PCR was performed using
this set of primers specific to rat tPA cDNA (forward primer: AAG GAG
GCT CAC GTC AGA CTG TA; reverse primer: CCT GCA CAC AGC ATG
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TTG CT). For control, uPA and glyceraldehyde-phosphate dehydroge-
nase (GAPDH) sets of primers were described previously (Bahi et al.
2004a, 2006).
The quantification was performed using the real-time PCR iCycler
(BioRad, Reinach, Switzerland ). For PCR, 5 ml cDNA preparation, 0.5
mM of forward and reverse primers and 10 ml of IQ SYBR Green
Supermix (Biorad) in a total volume of 20 ml were applied. The
following PCR program was performed: 3 min at 958C (initial
denaturation); 208C/second temperature transition rate up to 958C
for 45 seconds, 45 seconds 628C, repeated for 40 times (amplifica-
tion). The PCR reaction was evaluated by melting curve analysis
following the manufacturer’s instructions and checking the PCR
products on 2% agarose gel.
The PCR cycle number at which each assay target reached the
threshold detection line was determined (Ct value). Complementary
DNA samples were assayed on at least three dilutions to check for
assay reliability using duplicate assay on each dilution. The deltaCt for
each candidate was calculated as deltaCt ¼ [Ct (tPA or uPA)  Ct
(GAPDH)]. The relative abundance of tPA and uPA transcripts can be
calculated as the ratio between treated control samples (Bahi et al.
2004a, 2004b, 2005a, 2005b, 2006).
Stereotaxic surgeries
Lentiviral injections into the NAc were performed according to the
previous publications (Bahi et al. 2004a, 2004b, 2005a, 2005b,
2006). Briefly, rats were anesthetized with a mix of ketamine/
xylazine (100 mg/kg/10 mg/kg, intraperitoneal [i.p.]) and placed in
a stereotaxic apparatus. Using a 10-ml Hamilton syringe, 4 ml of
concentrated lentiviral stocks were injected into the NAc (þ1.4 mm
anteroposterior; 1.6 mm mediolateral from bregma and 6.8
dorsoventral from the skull; Paxinos & Watson 1998). Following
7 days recovery from the operation, rats were used for behavioral
studies.
Drug treatment
For tPA mRNA expression, the protocols used were described
previously (Bahi & Dreyer 2005). Amphetamine, morphine and
cocaine hydrochloride (Sigma) were dissolved in 0.9% physiological
saline. For single-injection treatments, rats were given a subcuta-
neous injection of morphine (10 mg/kg), amphetamine (2 mg/kg,
i.p.) or cocaine (20 mg/kg, i.p.).
Behavioral experiments
For acute effects, rats were injected saline (1 ml/kg) or drugs (either
morphine 10 mg/kg subcutaneously [s.c.], amphetamine 2 mg/kg, i.p.
or cocaine 20 mg/kg, i.p.) on day 1, and the locomotor activity was
measured for 180 min (morphine-injected animals) or 60 min (cocaine-
and amphetamine-injected rats).
For evaluation of sensitization effects, rats were injected drugs
(morphine 10 mg/kg, amphetamine 2 mg/kg, i.p., or cocaine 20 mg/
kg, i.p.) once per day for 24 days from days 2 to 24, and drug-induced
locomotor activity was measured every day for 180 min (morphine-
injected animals) or 60 min (cocaine- and amphetamine-injected
rats). Over this period of 24 days, rats were given normal water
supplemented with 5% sucrose during the first 10 days (days 1–10)
enabling to fully express the genes of interest. Then, during a second
session (days 11–17), rats were fed 0.02% doxycycline in the
drinking water (5% of sucrose) to inhibit expression of ectopic
tPA, uPA or GFP. Thereafter, in a third session (days 18–24), ectopic
gene expression was switched back by removing doxycycline from
the drinking water (5% sucrose). During these sessions, drug was
daily injected. Finally, drug was withdrawn for 2 weeks, and then
animals were challenged with one single injection of drug (same
doses) and the behaviors were measured (over 180 min for
morphine-injected animals or over 60 min for cocaine- and amphet-
amine-injected rats) (Bahi et al. 2004a, 2004b, 2005a, 2005b, 2006).
Conditioned place preference was performed as previously
described (Bahi et al. 2006). Briefly, in the preconditioning period,
the rat was allowed to move freely between two boxes (consisting of
either wire grid or mesh floor) daily for 20 min for 3 days (days 1–3).
On day 3, the amount of time spent in each chamber was monitored
and used to assess unconditioned preferences. Thereafter, during the
conditioning phase, the rat was injected on days 4, 6 and 8 either
morphine (10 mg/kg), amphetamine (2 mg/kg, i.p.) or cocaine (20 mg/
kg, i.p.) and immediately confined in the floor-mesh box for 20min. On
days 5, 7 and 9, the rat was injected saline (1 ml/kg) and placed in the
wire grid chamber for 20 min. During the conditioning phase,
chambers were never communicating and they were blocked by
a guillotine door. On day 10, the postconditioning conditioned place
preference test was performed without drug treatment. Animals
were placed between the two chambers with the guillotine door
removed and allowed free access to the entire set up. The time the rat
spent in each chamber was measured for 20 min. Drug-induced place
preference behavior was expressed by post versus pre, which was
calculated as: [(postvalue)  (prevalue)], where post- and prevalues
were the difference in time spent at the drug-conditioning site in the
postconditioning and preconditioning, periods, respectively.
Gel zymography
For sodium dodecyl sulphate–polyacrylamide gel electrophoresis
(SDS–PAGE) zymography, rats were killed at the end of locomotor
activity monitoring, brains quickly removed and NAc regions rapidly
dissected and used for protein extraction. The tissue was homoge-
nized in 0.5 ml of cold extraction buffer that contained 50 mM Tris–
HCl, pH 6.8, 0.05% Triton-X-100 and 2 mM ethylenediaminetetra-
acetic acid. The tissue homogenate was incubated for 15 min on ice
and vortexed. Then, the homogenate was centrifuged for 20 min at 10
000 g and the supernatant collected and stored at 808C. Protein
concentrations were measured using the Bradford method. Equal
amounts of protein extracts (10 mg) were mixed with nonreducing
SDS–PAGE sample buffer (62.4 mM Tris, pH 6.8, 20% glycerol, 2%
SDS) and run in a 10%SDS–PAGE gel containing 0.1% casein (Sigma)
and 12 mU/ml plasminogen (Calbiochem, Switzerland). After electro-
phoresis, the gel was washed four times for 30 min with 100 mM Tris–
HCl pH 8.0, 50mMMgCl2 and 2.5% Triton-X-100 solution. The gel was
then incubated overnight in 100 mM Tris–HCl, pH 8.1, and 15 mM
MgCl2 solution at 378C, stained with Coomassie brilliant blue (Sigma)
and destained with solution containing 35% methanol, 7% acetic
acid. Urokinase-type plasminogen activator and tPA activity were then
observed in the gel as light bands against a dark background.
Immunohistochemistry
Brain section staining was performed according to previously pub-
lished procedures (Bahi et al. 2004a). Briefly, rat brains were rapidly
removed and frozen in isopentane at 308C for 3 min and kept at –
258C. Coronal sections were cut at 14 mm in a cryostat (Leitz, Lucern,
Switzerland), placed on gelatinized glass slides and air dried at room
temperature for 20 min. Antigens were localized using the avidin–
biotin–peroxidase technique. Slices were fixed in 4% paraformalde-
hyde for 15 min and washed three times with 1 phosphate-buffered
saline (PBS). Endogenous peroxidase activity was quenched with 2%
hydrogen peroxide in water (H2O2) for 40 min at room temperature.
Non-specific binding was blocked for 30 min at room temperature in
1 PBS containing 1% bovine serum albumin, 1% Triton-X-100 and
3% normal goat serum. Sections were then rinsed and incubated
overnight with mouse anti-histidine antibody (MCA1396, 1:12 000;
Serotec, Du¨sseldorf, Germany) diluted in 1 PBS containing 1%
Triton-X-100 and 1% normal goat serum. Sections were then washed
three times with 1 PBS and incubated with the biotinylated
secondary antibody (goat anti-mouse immunoglobulin G, 1: 500;
Vector Laboratories, Burlingame, CA, USA) for 45 min at room
temperature. Sections were rinsed three times for 5 min in 1 PBS
at room temperature, followed by incubation in avidin–biotin complex
(Vector Laboratories) in 1 PBS solution. After three rinses in 1 PBS,
all sections were developed in 0.025% 3-30 diaminobenzidine tetrahy-
drochloride plus 0.02% H2O2 for 10–15 min. Sections were then
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dehydrated, mounted in permanent medium (Eukitt) and examined
with a Zeiss light microscope.
Statistical analysis
All data were expressed as the mean  SEM and analyzed using SPSS
v11 software. In the analysis of tPA mRNA expression, place
conditioning and locomotor activity test, statistical analysis was
performed using an analysis of variance (ANOVA), followed by the
Tuckey test when F ratios were significant (P < 0.05). Statistical
differences between groups were determined with the Mann–Whit-
ney U test. In the analysis of the time–course for chronic locomotor
sensitization, statistical differences between groups were deter-
mined by ANOVA with repeated measures.
Results
Previous studies have shown that cocaine induces uPA in
different brain area upon different paradigms of drug admin-
istration (Bahi et al. 2004a). Under similar conditions, cocaine
induced tPA mainly in chronic paradigms (Fig. 1). Under
chronic drug delivery, a 4.8-fold mRNA increase is observed
in the NAc (P < 0.05 compared with saline) and a 2.2-fold
increase was further observed in the VTA. Changes in
cocaine-mediated tPA mRNA induction were also very signif-
icant in the striatum (4.5-fold increase, P < 0.05) and in the
hippocampus (3.3-fold increase, P < 0.05). Acute treatment,
however, produced only slight but significant changes in the
NAc and the striatum (1.5- and 1.2-fold increase, respec-
tively), whereas in the other brain regions, tPA was not
induced, in contrast with observation reported under similar
conditions for uPA (Bahi et al. 2004a).
Lentiviruses expressing tPA or siRNAs targeted against
tPA have been prepared and tested in vitro in HEK293T-
infected cells (Fig. 2). Expression of tPA is titer dependent
and doxycycline regulatable. Coinfection of HEK293T cells
with various titers of LV-tPA and fixed levels of the doxycycline-
regulatable LV-uPA (Bahi et al. 2004a) induces titer-dependent
expression of tPAmRNA but does not influence expression of
the related uPA mRNA (Fig. 2).
HEK293T cells were coinfected with LV-tPA at fixed levels
and with three different LV-siRNAs, either alone or combined
(Fig. 3). As a control, LV-uPA was also coinfected in all
experiments. Control cells were infected with LV-uPA
together with LV-tPA (Fig. 3). As a result, LV-siRNAs had no
effects on uPA expression but strongly affected the expres-
sion of tPA, which was diminished to 78%, 43% and 62%,
respectively, in presence of LV-siRNA1, LV-siRNA2 or LV-
siRNA3 alone. Furthermore, when combined together, the
mix of LV-siRNAs induced a 92% decrease in tPA mRNA (P<
0.05 compared with control cells), whereas uPA mRNA
remains unaffected.
In vivo studies
Using these molecular tools and the tools previously
described (Bahi et al. 2004a, 2006), several groups of animals
were prepared, stereotaxically injecting lentiviruses into the
NAc and their behavioral activity in response to drugs was
measured. In an initial experiment (Fig. 4), one set of animals
was fed doxycycline, the other animals were fed without
doxycycline all through the experiments. Control groups were
injected LV-GFP into the NAc.
Effects of cocaine
Animals overexpressing tPA in the NAc show a 1.5-fold
increase in locomotor activity compared with GFP controls
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Figure 1: Changes in tPA mRNA expression after acute and
chronic cocaine injection in the brain. Rats were injected once
(acute) or during 2 weeks once a day (chronic) with 20 mg/kg i.p.
of cocaine and killed 24 h after the last injection. The different
brain areas were dissected out, total RNA was extracted and tPA
transcripts were quantified by mean of real-time PCR using
specific primers. Values indicate means  SEM. *P < 0.01 and
**P < 0.005 compared with saline-treated groups. #P < 0.01 and
##P < 0.005 compared with acute cocaine-treated groups. Coc,
cocaine 20 mg/kg; HIP, hippocampus; Sal, saline 1 ml/kg; STR,
striatum.
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Figure 2: In vitromanipulation of LV-tPA in HEK293T cells and quantification of tPA mRNA expression. HEK293T cells were co-
infected with 0, 3, 6 or 9 ml of LV-tPA together with 4 ml of LV-uPA-His6. Culture mediumwas supplemented with or without doxycycline
(30 ng/ml). After 72 h, culture mediumwas removed, total RNA was extracted and transcripts were quantified by mean of real-time PCR
using specific primers. Values indicate means  SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared with control cells.
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after acute cocaine injection (P < 0.05). Doxycycline restores
locomotor activity back to levels comparable with the GFP
controls (Fig. 4A). However, when tPA has been silenced, in
treated animals coinfected with LV-tPA-siRNAs – that also
silences the endogenously, cocaine-induced tPA – animals
show hypolocomotion and locomotor activity decreased to
0.7-fold the activity of the GFP control group (P < 0.05);
doxycycline had no effects on this group of animals (Fig. 4A).
In contrast, when uPA is overexpressed in the NAc while
endogenous tPA is silenced, animals show highest locomotor
activity, approximately 2.3-fold increase over GFP control
group (P < 0.05), but the effect was completely abolished
by downregulation of uPA in the NAc in the same animals fed
doxycycline (Fig. 4A). Injection of cocaine on these same
animals was continued for 24 days. Then, the animals were
submitted to a drug withdrawal period for 2 weeks and finally
challenged again with cocaine. Challenge immediately reca-
pitulated locomotor activity observed after acute drug treatment
(Fig. 4A0). Locomotor activity directly reflects expression of
uPA and tPA in the NAc (see later, Figs 6 and 8).
Effects of amphetamine and morphine
When animals were expressing tPA in the NAc, locomotor
activity after acute amphetamine administration increased
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Figure 3: In vitro changes of tPA mRNA expression and
inhibition with LV-tPA-siRNAs. HEK293T cells were infected
with 3 ml of LV-tPA together with 4 ml of LV-uPA-His6 alone
(control) or together with 2 ml of LV-GFP (LV-GFP); 2 ml of LV-tPA-
siRNA1; 2 ml of LV-tPA-siRNA2; 2 ml of LV-tPA-siRNA3 or all of the
LV-tPA-siRNAs together. After 72 h, total RNA was extracted and
transcripts were quantified by mean of real-time PCR using
specific primers. Values indicate means  SEM. *P < 0.05,
**P < 0.01, ***P < 0.001 compared with ‘control’ cells.
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Figure 4: Locomotor stimulating effect of acute cocaine, amphetamine and morphine injections and the locomotor
sensitization after single dose challenging with the same drugs. Rats (n ¼ 9) were stereotaxically injected with 4 ml of the
indicated lentiviruses; after recovery, open-field locomotor activity was achieved. Upper panels, acute injection: rats were injected saline
(1 ml/kg i.p.) and placed in the monitoring cages for 30 min and injected cocaine (20 mg/kg i.p.) (A), amphetamine (2 mg/kg i.p.) (B) or
morphine (10 mg/kg s.c.) (C) and monitored for one more hour (3 h after morphine injection). Lower panels, challenge after withrawal:
during 24 consecutive days, rats were injected with the indicated drugs using the same doses as for the acute procedure, followed by
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supplemented with 5% sucrose. Values indicate means  SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared with saline-treated
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compared with LV-tPA plus LV-tPA-siRNAs-injected animals.
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4.0-fold, compared with GFP control animals, whereas ani-
mals expressing uPA in the NAc show only an approximately
2.2-fold increase in locomotor activity over the GFP control
group (Fig. 4B, P < 0.01 and 0.05, respectively). Similarly,
acute morphine administration induced highest locomotor
activity in tPA-treated animals (1.8-fold increase compared
with GFP control animals, P < 0.01) over uPA-treated animals
(1.3-fold increase compared with GFP control animals, P <
0.05), in sharp contrast to observations made with cocaine
administration (Fig. 4C). As above, drug administration on
these same animals was continued for 24 days, and then the
animals were submitted to a drug withdrawal period for
2 weeks and finally challenged again with the drugs. Challenge
immediately recapitulated locomotor activity observed after
acute drug treatment (Fig. 4B0, C0).
Drug sensitization and effects of gene expression
In another experiment (Figs 5 and 6), animals were fed
without doxycycline for 10 days, then with doxycycline for
7 days and then again without doxycycline for another 7 days.
Drugs were injected daily during these three sessions. Finally,
drug was withdrawn for 15 days. At the end of that with-
drawal period animals were challenged with a single injection
of drug.
Under these conditions, animals show sensitization toward
cocaine, which markedly affects locomotor activity (Fig. 5).
When uPA is overexpressed in the NAc in presence of LV-
tPA-siRNAs – that also silence expression of endogenous tPA
under cocaine stimulation – locomotor activity is highest,
approximately 10- to 11-fold higher than saline control animals
(Fig. 5A0). Under these conditions, tPA-treated animals show
lower locomotor activity, approximately 7.5-fold higher than
saline controls (days 1–10). In all cases, suppressing tPA or
uPA expression in the NAc by doxycycline would suppress
the locomotor activity almost down to levels of the control
GFP animals (days 11–17), whereas doxycycline removal –
reinducing tPA or uPA expression in the NAc – reinstates the
initially observed behavioral effects of the animals (days 18–
24). Previous studies have shown that doxycycline sup-
presses uPA mRNA expression and affects uPA protein
expression within 24 h, whereas removal of doxycycline re-
expresses uPA mRNA and restores protein expression
after 24 h (Bahi et al. 2004a). Animals treated with LV-tPA-
siRNAs, – enabling silencing of both endogenous and ectopic
tPA – co-injected either with LV-tPA or with LV-uPA showed
little sensitization toward cocaine and their behaviors were
similar to GFP controls (Fig. 5A0).
Amphetamine-treated animals show a sharp drug-induced
sensitization. Locomotor activity is markedly stronger when
tPA is overexpressed compared with uPA (Fig. 5C0). Tissue-
type plasminogen activator induces a 10- to 12-fold increase
in locomotor activity, uPA a six- to eightfold, compared with
saline treatment. Both effects are doxycycline regulatable in
a reversible fashion (Fig. 5B0). In contrast tPA- or uPA-treated
animals show no sensitization when administered morphine
under chronic paradigm, whether tPA or uPA is overexpressed
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Figure 5: Locomotor stimulating effect of repeated cocaine, amphetamine and morphine injections. Rats (n ¼ 9) were
stereotaxically injected with 4 ml of the indicated lentiviruses; after recovery, open-field locomotor activity was achieved. Upper panels,
effects of saline. Rats were daily injected saline for 24 days (1 ml/kg i.p.) (A, B and C) and placed in themonitoring cages for 30min. Lower
panels, effects of drugs. About 30 min after saline injections, animals were injected either cocaine (20 mg/kg i.p.) (A0), amphetamine (2
mg/kg i.p.) (B0) or morphine (10 mg/kg s.c.) (C0) and monitored for one more hour (3 h after morphine injection). Injections were repeated
daily. From days 1 to 10, each group of animalswas fedwater supplementedwith 5% sucrose. The same animalswere then switched for
7 days to 0.02% doxycycline regimen in the drinking water supplemented with 5% sucrose (from days 11 to 17). Thereafter, animals
were switched back to doxycycline-free water for the last 7 days (from days 18 to 24). Values indicate means  SEM. Error bars have
been omitted from the points for the sake of clarity.
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or whether the exogenous protease is downregulated with
doxycycline (Fig. 5C0).
Behavioral effects and gene expression
The NAcs of treated animals were dissected out at the end
of series of behavioral measurements and mRNA levels
were measured relative to GAPDH. Observed locomotor
effects fully correlate with the levels of tPA and uPA mRNA
expressed in the different conditions (Fig. 6).
Cocaine administration. Animals treated with tPA showed
2.2-fold higher tPA mRNA expression (compared with GFP
control animals, P < 0.05) in acutely injected animals and the
ratio remained the same after the challenge (Fig. 6A, A$).
Note, however that the level of endogenous tPA increased
approximately 1.6-fold under these conditions, from approx-
imately 5.0 in acutely treated GFP animals to approximately
7.8 after challenge, reflecting cocaine-mediated induction of
endogenous tPA (Fig. 6A, A$). Animals treated with LV-tPA-
siRNAs did not reflect this increase in endogenous tPA upon
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Figure 6: mRNA expression changes of tPA and uPA after repeated cocaine, amphetamine andmorphine injections. Rats (n¼ 9)
were stereotaxically injected with 4 ml of the indicated lentiviruses. The NAcs of treated animals were dissected out at the end of series of
behavioral measurements and mRNA levels were measured relative to GAPDH. Animals were daily (for 24 days) injected saline (1 ml/kg
i.p.), placed in the monitoring cages for 60 min and injected cocaine (20 mg/kg i.p.) (A, A0 and A$), amphetamine (2 mg/kg i.p.) (B and B0) or
morphine (10 mg/kg s.c.) (C and C0>) and monitored. Upper panels (A, B and C): after 10 days some animals were killed, the NAc was
dissected out and mRNA prepared for quantitative real-time PCR. Middle panels (A0, B0 and C0): animals were daily (for 24 days) injected
drugs as above. From days 1 to 10, each group of animals was fed water supplemented with 5% sucrose. Then, animals were switched to
0.02% doxycycline regimen in the drinking water supplemented with 5% sucrose for 7 days (from days 11 to 17) and then animals were
killed, the NAcwas dissected out andmRNA prepared for quantitative real-time PCR. Lower panel (A$, left): animals were daily (for 24 days)
injected drugs as above. From days 1 to 10, each group of animals was fed water supplemented with 5% sucrose; then, animals were
switched to 0.02% doxycycline regimen in the drinkingwater supplementedwith 5% sucrose for 7 days. After that period, doxycyclinewas
removed and animals were further injected cocaine for 7 more days and then submitted to a drug withdrawal period for 2 weeks and finally
challenged again with cocaine (20 mg/kg), and killed. The NAc was dissected out and mRNA prepared for quantitative real-time PCR.
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cocaine injection (Fig. 6A, A$). Animals treated with uPA
showed 1.8-fold higher uPA mRNA expression (compared
with uPA in the GFP control group, P < 0.05) in acutely
injected animals (Fig. 6A); this was downregulated to basal
level by doxycycline (Fig. 6A0). In all groups, uPA was induced
upon cocaine delivery and its endogenous expression in the
GFP control group increased from approximately 5.5 after
acute injection up to approximately 7.5 after challenge (P <
0.05). Nevertheless, uPA induction in uPA-treated group after
challenge was only 1.3-fold higher than in the GFP group, P <
0.05 (Fig. 6A$).
Amphetamine and morphine administration. Animals treated
with tPA showed 1.8- and 1.9-fold increase in tPA mRNA
expression (compared with tPA expression in control groups,
P < 0.05), after acute administration of amphetamine or
morphine, respectively (Fig. 6B, C), whereas in uPA-treated
animals the levels of expression were identical to those found
in GFP control groups. By contrast, uPA levels of expression
after acute amphetamine or morphine administration were
identical to levels found in the GFP control groups but were
induced 2.5- and 1.9-fold, respectively, in the LV-uPA-treated
animals (Fig. 6B, C, P < 0.05). In all cases, doxycycline down-
regulated tPA or uPA expression back to levels similar to those
of the control GFP groups (Fig 6B0, C0).
Gene expression and place preference
Conditioned place preference was measured on animals
infected with the different lentiviruses in the NAc. Animals
expressing tPA show a 2.1-fold increase in place preference
for cocaine (20 mg/kg; Fig. 7A, P < 0.05). Silencing tPA in the
NAc suppressed place preference under these conditions
(Fig. 7A). Nevertheless, the observed effects were even
much higher with uPA-treated animals, which showed
a 3.6-fold increase in cocaine-induced place preference over
GFP-treated control animals (P< 0.01; Fig. 7A). Both amphet-
amine andmorphine induced the opposite effects: injection of
2 mg/kg amphetamine in tPA-treated animals induced a 2.9-
fold increase in place preference over GFP-treated control
animals, whereas in uPA-treated animals, amphetamine
induced only a 1.9-fold increase in place preference over
GFP-treated animals (Fig. 7B, P < 0.01 and 0.05, respec-
tively). Similarly, injection of 10 mg morphine induced a 3.5-
fold increase in tPA-treated animals and only a 2.2-fold
increase in uPA-treated animals compared with GFP-treated
controls (Fig. 7C, P < 0.01 and 0.05, respectively). Thus, tPA
clearly induces stronger place preference than uPA when
amphetamine or morphine is injected, whereas the reverse is
observed with cocaine.
To determine whether the observed induction of locomotor
activity and drug-induced place preference were correlated
with tPA and uPA protein expression, immunohistochemistry
was performed using specific His-tag antibodies (Fig. 8). The
tPA and uPA proteins were detected in cells of the NAc from
either cocaine-, amphetamine- and morphine-treated animals
(Fig. 8). No signal was detected in the brain sections of
animals co-injected with LV-tPA and LV-tPA-siRNAs following
drug administration (Fig. 8D, E, F). However, immunohisto-
chemistry showed that uPA immunoreactivity was highly
positive when LV-uPA lentiviral vectors were co-injected with
tPA-siRNAs-expressing vectors, supporting the idea that the
siRNAs used in this study were highly specific for the knock-
down of tPA transcripts and did not affect uPA expression
(Fig. 8G, H, I).
To determine whether observed behavioral changes are
related to protein expression only or whether the active form
of the enzymes are required, the enzymatic activities of tPA
and uPA have been determined by SDS–PAGE zymography
from tissue extracts after repeated amphetamine and cocaine
treatment. Overexpression of tPA and uPA results into
enhanced enzymatic activity of these proteases in the NAc
(Fig. 9) after repeated injections of cocaine and amphet-
amine. However, when gene expression of tPA and uPA
was inhibited with specific siRNA-expressing lentiviral vec-
tors, no enzymatic activity was observed. We observed also
an inhibition of these enzymatic activity when animals were
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Figure 7: Cocaine-, amphetamine- and morphine-induced place preference in tPA- and uPA-overexpressing animals after
stereotaxic injections. Rats (n ¼ 6) were stereotaxically injected with 4 ml of the indicated lentiviruses; after recovery, drugs-induced
place preference was achieved. Animals were conditioned using cocaine (20 mg/kg i.p.) (A), amphetamine (2 mg/kg i.p.) (B) or morphine
(10 mg/kg s.c.) (C). After 3-day habituation, rats were conditioned using the indicated drugs during the fourth, sixth and eighth days and
with saline during the fifth, seventh and ninth days. Rats were then tested for place preference in day 10 without any injection for 20 min.
Values indicate means  SEM. *P < 0.05, **P < 0.01 compared with LV-GFP-injected animals.
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injected with the mutated form of uPA ‘uPA-Mut’ where the
active site of the protease had been destroyed by site-
directed mutagenesis (Bahi et al. 2004b). Inhibition was also
detected when animals infected either with LV-uPA and LV-
tPA had been fed doxycycline (Fig. 9). This clearly shows that
the enzymes are active under normal conditions and suggests
that active forms of the enzymes are related to behavioral
changes. Furthermore, to check tPA-induced enzymatic
activity, animals were injected with LV-tPA together with LV-
uPA-siRNAs, but, as shown in Fig. 9, uPA-siRNAs, unlike tPA-
siRNAs, did not block tPA activity.
Discussion
Our data show that psychostimulants induce both tPA and
uPA in acute and chronic delivery, but cocaine induces
preferentially uPA, whereas amphetamine and morphine
induce preferentially tPA. Consistent with these findings,
animals overexpressing either tPA in the NAc show greater
locomotor activity and behavioral sensitization uponmorphine
or amphetamine treatments, whereas uPA-overexpressing
animals show higher activity upon cocaine treatment. These
effects could be fully suppressed when tPA or uPA had been
silenced or by suppressing ectopic enzyme expression.
Furthermore, uPA-overexpressing animals show enhanced
conditional place preference for cocaine compared with tPA-
overexpressing animals. In contrast, tPA-overexpressing ani-
mals showed greater behavioral sensitization and locomotor
activity when animals were administered amphetamine or
morphine, compared with uPA-overexpressing animals and
they showed greater preference for these drugs. Together
these, data add further evidence for a significant function of
extracellular proteases in addiction and clearly provide evi-
dence for a differential role of plasminogen activators in this
context. Clearly, uPA and tPA induce distinct behaviors,
which may be interpreted according to their differential
pattern of activation.
Plasminogen activators activate the conversion of plasmin-
ogen into plasmin, an active extracellular serine protease. The
role of plasmin in brain plasticity has been described in
development and also in the adult brain. Tissue-type plasmin-
ogen activator is involved in synaptic plasticity and remodeling
directly by itself, or indirectly by converting plasminogen to
plasmin. Tissue-type plasminogen activator is directly
involved in long-term potentiation (LTP) by acting on NMDA
receptors (Nicole et al. 2001; Shin et al. 2004) and it is induced
as an immediate early gene upon stimulation of NMDA
receptor (Qian et al. 1993). The tPA secreted in the extracel-
lular space either functions in the extracellular matrix as
a protease in synaptic plasticity (Baranes et al. 1998) or binds
to its cell surface receptor LRP and activates synaptic
potentiation via PKA (Zhuo et al. 2000). Furthermore, tPA is
involved in the late phase of long-term potentiation (Baranes
Figure 8: Plasminogen activators (tPA and uPA) immunohistochemistry at the site of stereotaxic injection of LV-tPA or LV-uPA
in the NAc. Animals were killed at the end of the experiment; brains were dissected out and processed for immunohistochemistry (see
Materials andmethods for details). Magnification 40. Rats were injectedwith LV-tPA (A, B and C); LV-tPAþ LV-tPA-siRNAs (D, E and F)
or LV-uPA þ LV-tPA-siRNAs (G, H and I). Different groups of rats were treated with cocaine (A, D and G), amphetamine (B, E and H) or
morphine (C, F and I).
9
ht
tp
://
do
c.
re
ro
.c
h
et al. 1998; Frey et al. 1996), learning and memory (Calabresi
et al. 2000; Seeds et al. 1995), excitotoxic neurodegeneration
(Siao et al. 2003; Tsirka et al. 1995), and regeneration or
recovery from injury in the nervous system (Siconolfi & Seeds
2001). On the other hand, neurite outgrowth (Krystosek &
Seeds 1981), cell migration (Moonen et al. 1982; Seeds et al.
1999) and tPA-induced amyloid-beta degradation (Melchor
et al. 2003; Tucker et al. 2000) are mediated by plasmin.
These findings indicate that tPA contributes to the regulation
of numerous aspects of synaptic plasticity and remodeling.
However, the role of uPA in these different paradigms has not
yet been fully described. Furthermore, it is unclear whether
the involvement in plasticity of uPA is dependent on plasmin-
related modification of extracellular matrix proteins, like tPA.
Exposure to amphetamine produces a long-lasting increase
in the length of dendrites and the number of branched spines
on medium spiny neurons (Koob & Nestler 1997; Robinson &
Kolb 1997). Morphine increases dopaminergic neurotrans-
mission in the NAc via the activation of dopamine cells in the
VTA, an area that possesses a high density of m-opioid
receptors. This activation results mainly from the disinhibition
of inhibitory GABAergic interneurons in the VTA (Bonci &
Williams 1997; Johnson & North 1992). Because synaptic
plasticity is strongly activated by psychostimulants and may
be a cause for long-term adaptive changes, it is reasonable to
assume that active plasmin plays a central function in
addiction. Indeed, the tPA–plasmin system plays an important
role in the rewarding and locomotor-stimulating effects of
morphine by regulating morphine-induced dopamine release
in the NAc (Nagai et al. 2004). Morphine treatment increases
not only tPA in the NAc but also inhibitor-1 of plasminogen
activator (PAI-1), a serine protease inhibitor that regulates
plasminogen activation (Nagai et al. 2005a). Similarly,
repeated methamphetamine treatment induces tPA expres-
sion in the frontal cortex, NAc, striatum and hippocampus,
whereas single methamphetamine treatment does not affect
tPA expression. In respect to cocaine, tPA knockout mice
show cocaine-induced locomotor activity at lower doses than
wild-type control mice and a greater degree of cocaine-
induced locomotor activity following repeated administration
(Ripley et al. 1999). Nevertheless, tPA knockout mice did not
show facilitation of acquisition of cocaine self-administration,
whereas the effects of behavioral sensitization in tPA knock-
out mice were reversed by microinjections of exogenous tPA
into the NAc (Ripley et al. 1999).
Our study show that uPA and tPA respond very differently
to psychostimulants. In agreement with findings by Nagai
et al. (2004, 2005b), we found that tPA overexpression enhan-
ces amphetamine and morphine behavioral sensitization.
With cocaine, however, according to Ripley et al. (1999),
tPA knockout mice are not sensitized when tPA is absent and,
if recombinant tPA is given back, they show a conditioned
place preference score almost identical to wild-type mice;
furthermore, at low doses of cocaine, tPA knockout mice
showed enhanced locomotor activity when compared with
their wild-type littermates and show increased behavioral
sensitization than wild type (Ripley et al. 1999). Therefore,
one would reasonably assume that if these mice were
injected with our LV-tPA, they would show less locomotor
activity to cocaine and less behavioral sensitization, which is
Figure 9: Enzymatic activity of plasminogen activators (tPA and uPA) in the rat brain after stereotaxic injection of LV-uPA (A)
or LV-tPA (B) and repeated cocaine and amphetamine treatments measured with SDS–PAGE zymography. Samples were
collected from the NAc regions and proteins were extracted as described inMaterial and methods. Note that uPA and tPA activities were
increased both after cocaine and amphetamine treatments. The enzymatic activity was inhibited when LV-tPA-siRNAs, LV-uPA-siRNAs
or LV-uPA-Mut was injected or when animals were fed doxycycline in the drinking water. Note that tPA activity was not inhibited with LV-
uPA-siRNAs indicating that siRNAs-expressing lentiviruses are highly specific.
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strikingly in contrast to our observations. Nevertheless,
developmental compensatory mechanisms cannot be
excluded in these processes and it is possible that uPA or
other matrix proteases can take over the function of tPA in
tPA knockout mice. Rescue experiments are planed with
these mice to settle this controversy.
On the other hand, the gene encoding tPA is regulated in
a cell-type-specific manner by a complex array of transcription
factors that include Sp-1, AP-2, tPACRE and CREB (Costa
et al. 2004). The specific roles of these transcription factors in
addiction remain to be described in more details to better
characterize the regulation of plasminogen activators in this
paradigm. Changes in tPA (and uPA) mRNA expression in the
brain reward pathway after repeated drug treatments may be
due at least in part to the alteration in the ratios of these
transcription factors. It is well established that CREB levels
are changed in the NAc after chronic drug treatments (Widnell
et al. 1996).
The tPA– and uPA–plasmin systems degrade several
extracellular matrix proteins (Schnaper 1995), including
laminin (Goldfinger et al. 2000). Laminin in the synaptic cleft
localizes calcium channels to the sites of active zones
(Sunderland et al. 2000) and may induce significant increase
in calcium levels (Bixby et al. 1994). Accordingly, it is
possible that psychostimulant-mediated induction of the
tPA–plasmin system may result in a malfunction of calcium
channel activity, leading to the reduction of dopamine
release, because the tPA–plasmin system is involved in
the regulation of dopamine release in the NAc (Ito et al.
2006). Activation of the tPA–plasmin system stimulates
protease-activated receptor-1 (PAR1; Kuliopulos et al.
1999), which in turn increases intracellular calcium mobili-
zation, leading to a potentiation of depolarization-evoked
dopamine release in the NAc (Dery et al. 1998). Microinjec-
tion of either tPA or plasmin significantly potentiates dopa-
mine release without affecting basal dopamine levels (Ito
et al. 2006). Dopamine release in the NAc was markedly
diminished in tPA knockout mice compared with wild type,
whereas microinjections of either exogenous tPA or plasmin
into the NAc of tPA knockout mice restored dopamine
release as observed in wild-type mice (Ito et al. 2006).
Furthermore, microinjection of a PAR1 antagonist, [tyr(-1)]-
thrombin receptor activating peptide 7, into the NAc signif-
icantly reduced morphine-induced dopamine release in the
NAc and hyperlocomotion although the treatment had no
effect on basal dopamine release and spontaneous locomo-
tor activity, suggesting that PAR1 is a target for the tPA–
plasmin system in the regulation of acute morphine-induced
dopamine release in the NAc (Ito et al. 2007).
Another pathway is also very relevant to drug-mediated tPA
and uPA expression. It has been shown that plasmin converts
the precursor pro-brain-derived neurotrophic factor (BDNF) to
mature BDNF in vitro and that this conversion is critical for the
expression of late-phase LTP in the mouse hippocampus
(Pang et al. 2004). Most of BDNF secreted by neurons
appears to be in the precursor form and the secretion of
pro-BDNF is activity dependent (Chen et al. 2004). Brain-
derived neurotrophic factor is released upon neuronal depo-
larization and triggers rapid intracellular signaling and action
potentials in neurons (Poo 2001), because BDNF promotes
the depolarization-evoked release of dopamine from mesen-
cephalic neurons (Blochl & Sirrenberg 1996). Therefore, the
tPA– and uPA–plasmin system, through the maturation of
BDNF, may regulate BDNF-mediated depolarization-evoked
dopamine release. Potentiation of excitatory synapses trig-
gers the release of glutamate, followed by evoked expression
of BDNF, which stimulates the expression and activation of
the proteolytic activity of plasminogen activators, tPA and
uPA. Either directly or indirectly via plasmin formation, this
system may act to cleave extracellular matrix molecules or
cell adhesion molecules, allowing structural changes associ-
ated with neuronal development or synaptic plasticity. Thus,
the neurotrophic activity by BDNF may manipulate long-
lasting structural plasticity through tPA. It is well established
that BDNF, administered directly into the VTA or NAc, causes
a profound increase in cocaine-induced locomotor activity and
in cocaine reward in several behavioral paradigms (Hall et al.
2003; Horger et al. 1999).
Our study shows that uPA and tPA respond very differently
to psychostimulants. We found that tPA overexpression
enhances cocaine, amphetamine and morphine behavioral
sensitization, which is in agreement with findings by Nagai
et al. (2004, 2005b) concerning amphetamine andmorphine in
tPA knockout mice. According to their data, tPA knockout
mice are not sensitized when tPA is absent, but if recombi-
nant tPA is given back, they show a conditioned place
preference score almost identical to wild-type mice.
Furthermore, our data suggest that the active forms of the
enzymes are required for drug sensitization. Nevertheless
additional studies, using dominant inactive constructs will be
needed. As a matter of fact, both the active and the inactive
forms of uPA may bind to its receptor uPAR and the
complexes may activate cellular transduction and intracellular
cytoskeletal arrangement. Similarly, the inactive and the
active forms of tPA bind different extracellular matrix mole-
cules. In addition, uPA appears to have protein-binding
characters different from tPA, because tPA but not uPA binds
fibrin.
Our findings raise several questions that cannot be fully
answered yet. Further studies will be required to determine
at which stage of addiction the genes are involved and
whether they are involved in the acquisition/learning phase
or in the expression/retrieval phase of drug preference. In
addition, psychostimulants induce a large cluster of gene
expression changes in the mesolimbic pathway. It is there-
fore well possible that the observed differential behaviors
may be correlated with drug-mediated coexpression of
several other specific partners, either of uPA or of tPA, for
example, uPAR, PAI-1, PAI-2, PAR1, and so forth, besides
components of several intracellular signal transduction cas-
cades. The identification of these partners will be important
for elucidation of the different mechanisms. Nevertheless,
the observed differences may be of pharmacological rele-
vance. We have shown that inhibition of uPA by B428,
a highly specific uPA inhibitor, fully blocks cocaine-mediated
locomotor activity (Bahi et al. 2006). A similar tPA-specific
inhibitor would be highly useful to prevent amphetamine and
morphine reward. Therefore, this study opens new paths to
better understanding the molecular basis of addiction and
possibly toward its treatment.
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We found that tPA and uPA expression is not much
affected by a single injection of cocaine but is highly induced
after multiple injections. Behavioral sensitization in turn
results from multiple molecular changes and structural syn-
aptic adaptations, affecting dendritic length and spine density.
We propose that plasminogen activators may play an impor-
tant role in these structural adaptations, in view of their
effects on extracellular matrix degradation (plasmin, laminin)
and on metalloproteases activation at the surface of the
neurons. Thus, tPA and uPA will induce long-lasting effects,
affecting structural changes leading to synaptic plasticity and
therefore to drug dependence.
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